NEW YORK, February 17 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities maintain their Buy rating on the shares of Fabrinet (NYSE: FN). The 12-month target price is set to $24.
In a research note published on February 16, the analysts state that they hosted Fabrinet’s CFO Mark Schwartz and Chief Strategy Officer John Marchetti for Mid-Atlantic investor meetings. Investors showed concerns on the progress of the Thailand recovery and end-demand trends. The recovery is progressing more quickly than assumed, and the production at the Pinehurst facility is mainly back to normal, as per the February 6th call. Building 6 will be completed by March end, when Fabrinet will have the capacity to support the quarterly revenue of nearly $250 million to $260 million.
The company sees March as the quarter to end setting up displaced lines, however, the next quarter will be focused on finalizing qualifications. Moreover, September may be Fabrinet’s first “back to normal” quarter, with revenue expected to return to previous levels. As revealed earlier, the process of insurance recovery is still ongoing, and the company expects recording an extra loss of between $44 million and $63 million in relation with customer equipment, which exceeds the $40 million loss recorded in the December quarter.
New York, August 16 (FinanceEnquiry.com) – Lethal bloodshed in Egypt increased terrors on the subject of the wider Mideast area, with crude-oil futures widening their increase on August 16 on related supply worries.
Toting up to an augment of 0.5 percent in session of yesterday on the...HTC Desire 500: Soon to Mark Noticeable Entry - August 13, 2013
New York, Aug 5 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Genesee & Wyoming Inc. (NYSE: GWR). The 12-month target price has been reduced...Deutsche Bank Securities Reiterates BUY Rating on Gentiva Health Services (NASDAQ: GTIV), Target Price Raised - August 5, 2013
New York, Aug 5 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their BUY rating on the shares of Gentiva Health Services Inc (NASDAQ: GTIV). The 12-month target price has been raised...September Palladium, October Platinum Descend; Gold Futures Too Skid - July 30, 2013
New York, July 30 (FinanceEnquiry.com) – With investors getting ready for an essential monetary-policy report from the Fed in prospect later this week, gold futures skidded in electronic trades on July...Asia Stocks Ascent; Copper Totters - July 30, 2013
New York, July 30 (FinanceEnquiry.com) – In view of the fact that investors set for the policy meeting of the Fed, the dollar index inched higher from a five-week low, whereas Asian stocks climbed up...Samsung Gravity Q T289: Serving Simplicity at its Best - July 30, 2013
New York, July 30 (FinanceEnquiry.com) – With the changing time, a huge transformation has been observed in the tastes and likings of the buyers. This is quite important to notice as a lot of mobile...Deutsche Bank Securities Reiterates HOLD Rating on The Wendy’s Company (NASDAQ: WEN), Target Price Raised - July 30, 2013
New York, July 30 (FinanceEnquiry.com) – Analysts at Deutsche Bank Securities reiterate their HOLD rating on the shares of The Wendy's Company (NASDAQ: WEN). The 12-month target price has been raised...Xolo A500: Simplicity Is Best - July 30, 2013
New York, July 30 (FinanceEnquiry.com) – In past few months, a lot of lately released Xolo handsets have gained huge popularity mostly because of few but important reasons, such as cost effectiveness, ‘easy...